New oral paclitaxel trial offers hope for Hard-to-Treat GIST
NCT ID NCT06326346
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an oral form of paclitaxel (Liporaxel) in 28 adults with advanced gastrointestinal stromal tumors (GIST) that no longer respond to three standard drugs: imatinib, sunitinib, and regorafenib. The study focuses on patients whose tumors have low levels of a protein called P-glycoprotein, which may make the drug more effective. Participants take Liporaxel twice daily on specific days each month, and researchers will track how well it controls tumor growth over 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral paclitaxel (Liporaxel)
What this could lead to
If it works, this could offer a new oral treatment option for GIST patients who have run out of standard therapies.
What could go wrong
This is a small early-phase trial with only 28 participants, so results may not apply broadly. The drug may not control tumor growth or could cause side effects like nerve damage or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center, University of Ulsan College of Medicine
RECRUITINGSeoul, Songpagu, 138-736, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••